Anti–CTLA-4 Antibody–Based Treatment in Patients With Metastatic Melanoma Experiencing Disease Progression on Relatlimab/Nivolumab
Source: The Asco Post, May 2022
In a study reported as a letter to the editor in The New England Journal of Medicine, Alexander M. Menzies, MD, and colleagues found that patients with metastatic melanoma who had progressive disease while receiving relatlimab/nivolumab had poor responses to anti–CTLA-4–based treatment.
As noted by the investigators, the recently reported RELATIVITY-047 trial showed improved progression-free survival with the combination of the anti–LAG-3 antibody relatlimab plus nivolumab vs nivolumab alone in previously untreated patients with metastatic melanoma. They further noted that in disease refractory to PD-1 inhibition, use of an anti–CTLA-4 antibody alone or combined with an anti–PD-1 antibody has shown meaningful activity, with this finding suggesting nonoverlapping mechanisms of antitumor immune activity.
The study involved pooled retrospective data on 36 patients from five international centers who experienced disease progression while receiving relatlimab/nivolumab who were subsequently treated with an anti–CTLA-4 antibody alone (n = 19) or in combination with an anti–PD-1 antibody (n = 17).